Blood: Three aspirin treatment options in optimizing isoplate hyperpluse patients with antiplatelet treatment comparison

Ispeciallyanocal hyperplasia (ET) is characterized by abnormal macrocytocell production and an increased risk of blood clotsDaily small-dose (od) aspirin is the recommended antithrombotic treatment, but platelet generation acceleration may shorten the time of platelet cyclooxidation (COX)-1 inhibitionrecently published a research article in Blood, the authoritative journal of the field of blood diseases, in which researchers conducted a multicenter, double-blind trial to explore the efficacy of three aspirin treatments that optimize platelet COX-1 inhibition while preserving COX-2-dependent vascular anticoagulant function245 patients with long-term od low-dose aspirin were randomly (1:1) given 100 mg aspirin, od, 2 times daily (bid) or 3 times a day (tid) for 2 consecutive weeksThe researchers measured the excretion of serum thrombosin B2 (sTXB2) (effective biomarkers of platelet COX-1 activity) and urethra cyclin metabolites (PGIM) as the main alternative endpoints for efficacy and safety, respectively, after randomized groupings and 2 weeksTX metabolites (TXM) excretion, gastrointestinal tolerance and ET-related symptoms in urine were also investigatedthe researchers found a significant reduction in individual variability between patients with bid and tid treatment regimens, and the median of sTXB2 was lower, with od group (n?85), bid group (n-79) and tid group (n-79) sTXB2 being: 19.3,9.7-40, 4.1-6.7, and 2.5.4-5.65/ng, respectivelyThe urine levels of PGIM were similar in three groups of patientsTXM was significantly reduced in the urine of patients in both groupsPatients in the tid group had a higher score of abdominal discomfortin general, the current recommended aspirin treatment for cardiovascular prophymalytic 75-100 mg od has significant disadvantages in reducing platelet activation in the vast majority of ET patientsThe antiplatelet effect of small doses of aspirin can be significantly improved by shortening the time between administration slower to 12 hours, while further reducing the interval between administrations is not beneficial